Last $5.32 USD
Change Today +0.12 / 2.31%
Volume 832.4K
PGNX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for progenics pharmaceuticals (PGNX)

Year over year, Progenics Pharmaceuticals, Inc. has seen revenues fall from $14.0M USD to $7.8M USD. In addition, the company has been unable to reduce the percentage of sales devoted to cost of goods sold, SGA expenses and income tax expenses. This has led to a reduction in the bottom line from a loss of $35.4M USD to an even larger loss of $42.6M USD.
Currency in
Millions of US Dollars
As of:Dec 31
2010
Dec 31
2011
Dec 31
2012
Dec 31
2013
4 Year
Trend
Revenues7.884.614.07.8
Other Revenues0.10.20.10.1
TOTAL REVENUES8.084.814.07.9
Cost of Goods Sold52.254.133.534.7
GROSS PROFIT-44.230.7-19.5-26.9
Selling General & Admin Expenses, Total22.818.214.713.3
Depreciation & Amortization, Total2.92.11.30.9
OTHER OPERATING EXPENSES, TOTAL25.720.316.014.2
OPERATING INCOME-69.910.3-35.5-41.1
Interest and Investment Income0.10.10.10.0
NET INTEREST EXPENSE0.10.10.10.0
EBT, EXCLUDING UNUSUAL ITEMS-69.810.4-35.4-41.1
Merger & Restructuring Charges--0.0---0.8
Other Unusual Items, Total-------1.1
Other Unusual Items------0.2
EBT, INCLUDING UNUSUAL ITEMS-69.810.4-35.4-42.9
Income Tax Expense-0.1-----0.4
Earnings from Continuing Operations-69.710.4-35.4-42.6
NET INCOME-69.710.4-35.4-42.6
NET INCOME TO COMMON INCLUDING EXTRA ITEMS-69.710.4-35.4-42.6
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS-69.710.4-35.4-42.6
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $5.32 USD +0.12

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.79 USD +0.28
Dynavax Technologies Corp $1.34 USD -0.01
Genocea Biosciences Inc $11.65 USD +0.57
Rigel Pharmaceuticals Inc $2.20 USD -0.03
ZIOPHARM Oncology Inc $3.05 USD +0.05
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.